Drugs shares sale nets founders pounds 17m
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PAUL DRAYSON, founder and chief executive of Oxford-based Powderject Pharmaceuticals, and his wife Elspeth yesterday netted pounds 17m from the sale of 15 per cent of their shares in the company.
The couple, who gave their life savings of around pounds 100,000 to found Powderject, put an undisclosed proportion of the funds into a charitable trust and gave pounds 1.2m to the John Radcliffe hospital in Oxford. Dr Drayson said they had made the donation after his wife gave birth in the hospital on Saturday.
The placing, at 800p, of over 9 million shares belonging to founder shareholders followed the expiry of a lock-up period initiated upon the company's flotation two years ago.
The Draysons' options were exercised at just 10p per share. The couple have entered a new agreement which forbids them from selling their remaining 12 per cent Powderject holding until the company is profitable. The rest of the management have signed a new lock-up lasting one year.
Meanwhile, Powderject said Glaxo Wellcome had paid $3.4m (pounds 2.2m) for two further licences to use its patented powderject system, an alternative to needle-based drug delivery methods, in vaccines. The shares closed up 15p at 845p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments